PFE disclosed on today’s 3Q15 CC that the FDA issued a CRL for the 351(k) application submitted by HSP (prior to PFE’s buyout). PFE said it would resubmit the aBLA with additional data.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”